Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
1. A compound that is one of the following compounds set forth in Table 1A, Table 1B, or a pharmaceutically acceptable salt thereof:
TABLE 1A
Cpd
No.
Structure
1
2
3
5
6
7
8
9
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
TABLE 1B
Cpd
No.
Structure
27
28
29
30
31
32
33
34
35
36
2. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is
4. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carrier or excipient.
11. A pharmaceutical composition comprising a compound according to claim 2 and one or more pharmaceutically acceptable carrier or excipient.
12. A pharmaceutical composition comprising a compound according to claim 3 and one or more pharmaceutically acceptable carrier or excipient.
13. A method of treating a disease or disorder which can be ameliorated by KCNQ2/3 potassium channel opening, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
14. The method of claim 13 , wherein the disease or disorder is epilepsy.
15. A method of treating a disease or disorder which can be ameliorated by KCNQ2/3 potassium channel opening, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 2 .
16. The method of claim 15 , wherein the disease or disorder is epilepsy.
17. A method of treating a disease or disorder which can be ameliorated by KCNQ2/3 potassium channel opening, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 3 .
18. The method of claim 17 , wherein the disease or disorder is epilepsy.